Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma

Hepatology Research

Volumn 38, Issue 5, 2008, Pages 474-483

  Yoshikawa, Masaharu ^a   Ono, Naofumi ^b   Yodono, Hiraku ^c   Ichida, Takafumi ^d   Nakamura, Hironobu ^e  

^a CHIBA UNIVERSITY   (Japan)

^b Eguchi Hospital   (Japan)

^c Narumi Hospital   (Japan)

^d Shizuoka Hospital   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Cisplatin; Hepatocellular carcinoma; Transcatheter arterial infusion

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DOXORUBICIN; EPIRUBICIN; GAMMA GLUTAMYLTRANSFERASE; MITOMYCIN C; PROTEIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART INFARCTION; HEPATIC ARTERY; HUMAN; HYPOCHROMISM; INOPERABLE CANCER; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POWDER; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 42649086177     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00338.x     Document Type: Article

References (24)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-37.
2. Carr BI. Hepatocellular carcinoma. Current management and future trends. Gastroenterology 2004; 127: S218-24.
3. Shiu W, Leung N, Li M, Leung WT, Li AK. The efficacy of high-dose 4′epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol 1988; 18: 235-7.
4. Nagahama H, Okuda S, Okusaka T et al. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 1997; 27: 321-4.
5. Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimada Y. Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 1988; 24: 1897-8.
6. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m 2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68: 487-91.
7. Yamamoto K, Shimizu T, Narabayashi I. Intra-arterial infusion chemotherapy with lipiodol-CISPLATIN suspension for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2000; 23: 26-39.
8. Maeda S, Shibata J, Fujiyama S et al. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 809-13.
9. Ikeda M, Maeda S, Shibata J et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66: 24-31.
10. Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. Cancer 2002; 95: 588-95.
11. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002; 62: 69-73.
12. World Health Organization. WHO handbook for reporting results of cancer treatment, Vol. 48. Geneva: World Health Organization, 1979.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51.
15. Taguchi T, Saito T, Ota J et al. Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Jpn J Cancer Chemother 1991; 18: 1665-75.
16. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103: 756-62.
17. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22.
18. Court WS, Order SE, Siegel JA et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20: 613-25.
19. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer 1986; 58: 2386-8.
20. Nagasue N, Yukaya H, Okamura J et al. Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Jpn J Cancer Chemoth 1986; 13: 2786-92.
21. Shepherd FA, Evans WK, Blackstein ME et al. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 1987; 5: 635-40.
22. Makela J, Tikkakoshi T, Leinonen A, Siniluoto T, Karttunen A, Kairaluor MI. Superselective intra-arterial chemotherapy with mitomycin C in hepatic neoplasms. Eur J Surg Oncol 1993; 19: 348-54.
23. Okada S, Okazaki N, Nose H et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993; 50: 22-6.
24. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.